Shenzhen Chipscreen Biosciences Future Growth
Future criteria checks 2/6
Shenzhen Chipscreen Biosciences is forecast to grow earnings and revenue by 64.9% and 28.6% per annum respectively. EPS is expected to grow by 64.7% per annum. Return on equity is forecast to be -0.9% in 3 years.
Key information
64.9%
Earnings growth rate
64.7%
EPS growth rate
| Pharmaceuticals earnings growth | 18.3% |
| Revenue growth rate | 28.6% |
| Future return on equity | -0.9% |
| Analyst coverage | Low |
| Last updated | 30 Oct 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1,224 | 11 | N/A | 143 | 1 |
| 12/31/2025 | 938 | -80 | N/A | 77 | 1 |
| 12/31/2024 | 705 | -160 | N/A | 48 | 1 |
| 9/30/2024 | 656 | -70 | -188 | 29 | N/A |
| 6/30/2024 | 584 | -108 | -217 | -20 | N/A |
| 3/31/2024 | 548 | 103 | -293 | -73 | N/A |
| 12/31/2023 | 524 | 89 | -386 | -157 | N/A |
| 9/30/2023 | 543 | 168 | -358 | -70 | N/A |
| 6/30/2023 | 556 | 192 | -357 | -101 | N/A |
| 3/31/2023 | 532 | -11 | -403 | -17 | N/A |
| 12/31/2022 | 530 | 17 | -357 | 43 | N/A |
| 9/30/2022 | 490 | 4 | -381 | 70 | N/A |
| 6/30/2022 | 463 | 10 | -312 | 130 | N/A |
| 3/31/2022 | 460 | 26 | -180 | 112 | N/A |
| 12/31/2021 | 430 | 22 | -164 | 125 | N/A |
| 9/30/2021 | 360 | -32 | -215 | 74 | N/A |
| 6/30/2021 | 342 | -5 | -231 | 54 | N/A |
| 3/31/2021 | 312 | 19 | -219 | 90 | N/A |
| 12/31/2020 | 269 | 31 | -243 | 94 | N/A |
| 9/30/2020 | 231 | 37 | -185 | 91 | N/A |
| 6/30/2020 | 202 | 31 | -201 | 36 | N/A |
| 3/31/2020 | 181 | 23 | -201 | -6 | N/A |
| 12/31/2019 | 174 | 19 | -158 | -25 | N/A |
| 9/30/2019 | 181 | 37 | -130 | -16 | N/A |
| 6/30/2019 | 157 | 31 | N/A | N/A | N/A |
| 3/31/2019 | 142 | 28 | -91 | 40 | N/A |
| 12/31/2018 | 148 | 31 | -118 | 23 | N/A |
| 12/31/2017 | 111 | 24 | N/A | 3 | N/A |
| 12/31/2016 | 85 | 5 | N/A | 60 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 688321 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 688321 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 688321 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 688321's revenue (28.6% per year) is forecast to grow faster than the CN market (13.8% per year).
High Growth Revenue: 688321's revenue (28.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 688321 is forecast to be unprofitable in 3 years.